Accelerating drug discovery
As shown by our pipeline, our platform has already proven its potential in boosting the identification of drug candidates for a range of complex biological targets across multiple therapeutic areas.
Multiple projects, including de novo drug design and drug repurposing strategies, have already progressed through to late-stage clinical trials. These include projects with a high medical need, such as viral infection, ophthalmology, oncology and immune diseases.
Our pipeline consists of three areas:
Wholly Owned
Our wholly owned pipeline for which we’ve used the Exscalate platform to progress internal projects towards the clinical stage.
Disease area | Target | Mechanism of action | Co-developed partner | |
---|---|---|---|---|
Immunology | C5A inhibitor | Negative allosteric modulator | Not partnered | |
Inflammatory/Metabolic | GPR120 | Positive allosteric modulator | Not partnered | |
Autoimmunity/Psoriasis (Derma) | IL-17 inhibitor | Negative allosteric modulator | Not partnered | |
IBD/IPF/Scleroderma/Ocular | CB2 Agonists | Undisclosed | Not partnered | |
Undiscolsed | Angiogenic peptides | Negative allosteric modulator | Not partnered |
Immunology
Target: C5A inhibitor
Mechanism of action: Negative allosteric modulator
Project status:
Co-developed partner: Not partnered
Inflammatory/Metabolic
Target: GPR120
Mechanism of action: Positive allosteric modulator
Project status:
Co-developed partner: Not partnered
Autoimmunity/Psoriasis (Derma)
Target: IL-17 inhibitor
Mechanism of action: Negative allosteric modulator
Project status:
Co-developed partner: Not partnered
IBD/IPF/Scleroderma/Ocular
Target: CB2 Agonists
Mechanism of action: Undisclosed
Project status:
Co-developed partner: Not partnered
Undiscolsed
Target: Angiogenic peptides
Mechanism of action: Negative allosteric modulator
Project status:
Co-developed partner: Not partnered
Co-developed with a biopharma partner
Exscalate supports the identification of highly selective compounds for complex biological targets through drug development partnerships with innovative global biopharma companies.
For instance, we supported Aramis BioScience (a Harvard University spin-off) in identifying a novel agent for Dry Eye disease. This project has already reached the clinical stage. We also embarked on a journey with Engitix Therapeutics to develop a pipeline in fibrosis and cancer.
Disease area | Target | Mechanism of action | Co-developed partner |
---|---|---|---|
Ophta - Dry Eye | Undisclosed | Negative allosteric modulator | Aramis Biosciences |
Fibrosis | Undisclosed | Undisclosed | Engitix Therapeutics |
Cancer | Undisclosed - Multi Target | Undisclosed | Engitix Therapeutics |
Cancer | Undisclosed - Multi Target | Undisclosed | Engitix Therapeutics |
Ophta - Dry Eye
Target: Undisclosed
Mechanism of action: Negative allosteric modulator
Project status:
Co-developed partner: Aramis Biosciences
Fibrosis
Target: Undisclosed
Mechanism of action: Undisclosed
Project status:
Co-developed partner: Engitix Therapeutics
Cancer
Target: Undisclosed - Multi Target
Mechanism of action: Undisclosed
Project status:
Co-developed partner: Engitix Therapeutics
Cancer
Target: Undisclosed - Multi Target
Mechanism of action: Undisclosed
Project status:
Co-developed partner: Engitix Therapeutics
Co-developed with research or academic collaborations
As a member of a research or academic consortium, Exscalate has supported the identification of drug candidates that interact with multiple targets, known as polypharmacology.
For example, the Exscalate platform was used in the Exscalate4Cov project to identify the Raloxifene drug for use against Covid-19 and in the Antrarex4Zika project to identify active compounds against Zika virus.
Disease area | Target | Mechanism of action | Co-developed partner |
---|---|---|---|
Infective - Covid Raloxifene | Poly-phamarcology | Multiple MOA | Exscalate4COV |
Infective - Zika | Poly-phamarcology | Multiple MOA | Antarex4Zika |
Infective - Covid Raloxifene
Target: Poly-phamarcology
Mechanism of action: Multiple MOA
Project status:
Co-developed partner: Exscalate4COV
Infective - Zika
Target: Poly-phamarcology
Mechanism of action: Multiple MOA
Project status:
Co-developed partner: Antarex4Zika
Publications
Publications and articles demonstrating the use of the Exscalate platform in drug discovery programs in our pipeline:
ProfhEX: AI-based platform for small molecules liability profiling
MEDIATE - Molecular Docking at home: Turning collaborative simulations into therapeutic solutions
Relevance of Spike/Estrogen Receptor-α interaction for endothelial-based coagulopathy induced by SARS-CoV-2
Structure of human TRPM8 channel
Computational Insights into the Sequence-Activity Relationships of the NGF(1–14) Peptide by Molecular Dynamics Simulations
Structural Evolution of Delta (B.1.617.2) and Omicron (BA.1) Spike Glycoproteins
Cytopathic SARS-CoV-2 screening on VERO-E6 cells in a large-scale repurposing effort
Extensive Sampling of Molecular Dynamics Simulations to Identify Reliable Protein Structures for Optimized Virtual Screening Studies: The Case of the hTRPM8 Channel
EXSCALATE: An Extreme-Scale Virtual Screening Platform for Drug Discovery Targeting Polypharmacology to Fight SARS-CoV-2
Paclitaxel binds and activates C5aR1: A new potential therapeutic target for the prevention of chemotherapy-induced peripheral neuropathy and hypersensitivity reactions
Partnerships
We have formed many successful partnerships. Together we are accelerating drug discovery.